{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:39Z","timestamp":1790951439521,"version":"4.1.0"},"reference-count":102,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Platelets play a significant role in hemostasis, forming plugs at sites of vascular injury to limit blood loss. However, if platelet activation is not controlled, it can lead to thrombotic events, such as myocardial infarction and stroke. To prevent this, antiplatelet agents are used in clinical settings to limit platelet activation in patients at risk of arterial thrombotic events. However, their use can be associated with a significant risk of bleeding. An enhanced comprehension of platelet signaling mechanisms should facilitate the identification of safer targets for antiplatelet therapy. Over the past decade, our comprehension of the breadth and intricacy of signaling pathways that orchestrate platelet activation has expanded exponentially. Several recent studies have provided further insight into the regulation of platelet signaling events and identified novel targets against which to develop novel antiplatelet agents. Antiplatelet drugs are essential in managing atherothrombotic vascular disease. The current antiplatelet therapy in clinical practice is limited in terms of safety and efficacy. Novel compounds have been developed in response to patient variability and resistance to aspirin and\/or clopidogrel. Recent studies based on randomized controlled trials and systematic reviews have definitively demonstrated the role of antiplatelet therapy in reducing the risk of cardiovascular events. Antiplatelet therapy is the recommended course of action for patients with established atherosclerosis. These studies compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention. However, in patients undergoing percutaneous coronary intervention, it is still unclear whether the efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy depends on the type of P2Y12 inhibitor. This paper focuses on the advanced-stage evaluation of several promising antiplatelet drugs.<\/jats:p>","DOI":"10.3390\/ijms25147575","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:47:41Z","timestamp":1720774061000},"page":"7575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-5360","authenticated-orcid":false,"given":"Francesco","family":"Nappi","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/ATVBAHA.110.207522","article-title":"Signaling during platelet adhesion and activation","volume":"30","author":"Li","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2011.04361.x","article-title":"Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke","volume":"9","author":"Nieswandt","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jth.13302","article-title":"Platelet signaling: A complex interplay between inhibitory and activatory networks","volume":"14","author":"Bye","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","first-page":"e240133","article-title":"Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis","volume":"20","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/S0735-1097(02)02831-0","article-title":"Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention","volume":"41","author":"Mehta","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ahj.2008.06.003","article-title":"Current antiplatelet therapies: Benefits and limitations","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/ATVBAHA.118.310224","article-title":"Platelet Signaling Pathways and New Inhibitors","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-Month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): A randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_14","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: An individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2018.3197","article-title":"Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: A randomized clinical trial","volume":"319","author":"Zhao","year":"2018","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: Individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2125.2011.04049.x","article-title":"Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants","volume":"73","author":"Kelly","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Akkaif, M.A., Daud, N.A.A., Noor, D.A.M., Sha\u2019aban, A., Kader, M.A.S.A., and Ibrahim, B. (2024). The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing. Cardiovasc. Drugs Ther., online ahead of print.","DOI":"10.1007\/s10557-024-07544-6"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10760296241244772","DOI":"10.1177\/10760296241244772","article-title":"Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial","volume":"10","author":"Masson","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_33","first-page":"CD005158","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease","volume":"3","author":"Keller","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1152\/physiol.00020.2016","article-title":"New concepts and mechanisms of platelet activation signaling","volume":"32","author":"Estevez","year":"2017","journal-title":"Physiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/ATVBAHA.116.308763","article-title":"Newly formed reticulated platelets undermine pharmacokinetically short-lived antiplatelet therapies","volume":"37","author":"Armstrong","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/ATVBAHA.115.306885","article-title":"Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis","volume":"36","author":"Gremmel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejmech.2015.10.055","article-title":"New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors","volume":"107","author":"Yanachkov","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","article-title":"Antiplatelet and anticoagulation therapy for acute coronary syndromes","volume":"114","author":"Bhatt","year":"2014","journal-title":"Circ. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jacc.2008.05.031","article-title":"Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease","volume":"52","author":"Guthikonda","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/ATVBAHA.115.307097","article-title":"Simultaneous platelet P2Y12 and P2Y1 ADP receptor blockade: Are two better than one?","volume":"36","author":"Vaduganathan","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMe0706859","article-title":"Intensifying platelet inhibition\u2013navigating between Scylla and Charybdis","volume":"357","author":"Bhatt","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/ATVBAHA.116.307401","article-title":"P2Y12 receptor modulates sepsis-induced inflammation","volume":"36","author":"Liverani","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/09537104.2013.809520","article-title":"Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis","volume":"25","author":"Rahman","year":"2014","journal-title":"Platelets"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: A systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5551\/jat.63000","article-title":"Meta-analysis of short vs. prolonged dual antiplatelet therapy after drug-eluting stent implantation and role of continuation with either aspirin or a P2Y12 inhibitor thereafter","volume":"29","author":"Lahu","year":"2022","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e000703","DOI":"10.1161\/JAHA.112.000703","article-title":"High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)","volume":"1","author":"Pettersen","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1538-7836.2004.01017.x","article-title":"A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and Creactive protein following myocardial infarction: The CADET trial","volume":"2","author":"Woodward","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 348, 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e015560","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial","volume":"10","author":"Vranckx","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A critical appraisal of aspirin in secondary prevention","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/eurheartj\/ehz185","article-title":"Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: The TiCAB trial","volume":"40","author":"Schunkert","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial","volume":"289","author":"Gorelick","year":"2003","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0735-1097(01)01164-0","article-title":"Ticlopidine versus aspirin after myocardial infarction (STAMI) trial","volume":"37","author":"Scrutinio","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients","volume":"321","author":"Hass","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health registry","volume":"30","author":"Alberts","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0140-6736(99)04470-0","article-title":"Evidence of a chronic systemic cause of instability of atherosclerotic plaques","volume":"355","author":"Rothwell","year":"2000","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1161\/STROKEAHA.107.488387","article-title":"Progression of carotid stenosis detected by duplex ultrasonography predicts adverse outcomes in cardiovascular high-risk patients","volume":"38","author":"Sabeti","year":"2007","journal-title":"Stroke"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0016-5085(89)80056-3","article-title":"Aspirin-induced gastric mucosal injury: Lessons learned from animal models","volume":"96","author":"Kauffman","year":"1989","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jcin.2022.08.009","article-title":"P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention","volume":"15","author":"Greco","year":"2022","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_71","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"Damen","year":"2019","journal-title":"EuroIntervention"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Sec- ond-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: Randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"k3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST- elevation myocardial infarction (DAPT-STEMI): Randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial","volume":"14","author":"Hong","year":"2021","journal-title":"One-Mon. DAPT Investig. JACC Cardiovasc. Interv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: A population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2023.05.022","article-title":"The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease: Ring Out the Old?","volume":"82","author":"Kumbhani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: A systematic review and meta-analysis","volume":"142","author":"Murphy","year":"2020","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2020.11.046","article-title":"Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes","volume":"77","author":"Leonardi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ehjcvp\/pvac040","article-title":"Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events","volume":"8","author":"Tamargo","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","article-title":"Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: A MASTER DAPT trial sub-analysis","volume":"43","author":"Valgimigli","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/ATVBAHA.115.306777","article-title":"Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease","volume":"36","author":"Gurbel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (Protease- Activated Receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/ATVBAHA.116.308604","article-title":"Trowaglerix venom polypeptides as a novel antithrombotic agent by targeting immunoglobulin-like domains of glycoprotein VI in platelet","volume":"37","author":"Chang","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/ATVBAHA.115.306883","article-title":"The Novel Oral Syk Inhibitor, Bl1002494, protects mice from arterial thrombosis and thromboinflamma- tory brain infarction","volume":"36","author":"Stegner","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: The lessons from antagonizing the cellular effects of Thrombin\u2013Acute Coronary Syndromes Trial","volume":"123","author":"Bhatt","year":"2011","journal-title":"Circulation."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.tips.2012.07.004","article-title":"Platelet GPVI: A target for antithrombotic therapy?!","volume":"33","author":"Bender","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_99","first-page":"59","article-title":"Targeting GPVI as a novel antithrombotic strategy","volume":"5","author":"Andrews","year":"2014","journal-title":"J. Blood Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH13-01-0014","article-title":"12-lipoxygenase activity plays an important role in PAR4 and GPVI- mediated platelet reactivity","volume":"110","author":"Yeung","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","article-title":"Platelet 12-LOX is essential for Fc\u03b3RIIa- mediated platelet activation","volume":"124","author":"Yeung","year":"2014","journal-title":"Blood."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.tips.2017.08.001","article-title":"Targeting 12-Lipoxygenase as a potential novel antiplatelet therapy","volume":"38","author":"Tourdot","year":"2017","journal-title":"Trends Pharmacol. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/14\/7575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:12:53Z","timestamp":1760109173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/14\/7575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":102,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25147575"],"URL":"https:\/\/doi.org\/10.3390\/ijms25147575","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]}}}